

Conejo-Garcia J Or Conejo-Garcia Jr Or Conejo Jr Or Garcia Jr Forssmann

List of Publications by Year in
Descending Order

Source:

<https://exaly.com/author-pdf/684794/conejo-garcia-j-or-conejo-garcia-jr-or-conejo-jr-or-garcia-jr-forssmann-publications>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163
papers

15,334
citations

55
h-index

123
g-index

197
ext. papers

18,084
ext. citations

11.2
avg, IF

5.96
L-index

#	Paper	IF	Citations
163	TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures.. <i>Immunity</i> , 2022 , 55, 115-128.e9	32.3	2
162	Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort.. <i>Genome Medicine</i> , 2022 , 14, 35	14.4	1
161	Genomic and single-cell landscape reveals novel drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma.. <i>Cancer Discovery</i> , 2022 ,	24.4	3
160	Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells.. <i>Cancer Cell</i> , 2022 ,	24.3	2
159	Tumor-intrinsic PD-L1 promotes DNA repair in distinct cancers and suppresses PARP inhibitor-induced synthetic lethality.. <i>Cancer Research</i> , 2022 ,	10.1	3
158	Tumor expression quantitative trait methylation screening reveals distinct CpG panels for deconvolving cancer immune signatures.. <i>Cancer Research</i> , 2022 ,	10.1	1
157	Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma.. <i>PLoS ONE</i> , 2022 , 17, e0264014	3.7	0
156	CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from PD-L1 and include tissue-selective T cell activation 2021 , 9,		5
155	Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. <i>Molecular Therapy</i> , 2021 , 29, 1541-1556	11.7	3
154	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. <i>Blood</i> , 2021 , 137, 2621-2633	2.2	23
153	The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. <i>Frontiers in Immunology</i> , 2021 , 12, 694079	8.4	0
152	Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. <i>Nature Reviews Urology</i> , 2021 , 18, 543-555	5.5	5
151	Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 425-435	4	8
150	IgA transcytosis and antigen recognition govern ovarian cancer immunity. <i>Nature</i> , 2021 , 591, 464-470	50.4	28
149	The prognostic and predictive implications of the 12-chemokine score in muscle invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 466-466	2.2	1
148	Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	1
147	Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 710-718	4	1

146	The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community. <i>Frontiers in Immunology</i> , 2021 , 12, 735609	8.4	2
145	Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. <i>Nature Medicine</i> , 2021 , 27, 1410-1418	50.5	31
144	Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center. <i>Leukemia and Lymphoma</i> , 2021 , 1-8	1.9	
143	B cells and cancer. <i>Cancer Cell</i> , 2021 , 39, 1293-1296	24.3	6
142	Wide and deep learning for automatic cell type identification. <i>Computational and Structural Biotechnology Journal</i> , 2021 , 19, 1052-1062	6.8	4
141	Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 2021 , 60, 138-150	5	2
140	IgA-dominated humoral immune responses govern patients' outcome in endometrial cancer. <i>Cancer Research</i> , 2021 ,	10.1	1
139	Loss of microRNA-21 leads to profound stromal remodeling and short survival in K-Ras-driven mouse models of pancreatic cancer. <i>International Journal of Cancer</i> , 2020 , 147, 2265-2278	7.5	8
138	Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer 2020 , 8,		4
137	The Association of Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1792-1799	4	5
136	Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial 2020 ,		7
135	c-Maf: a bad influence in the education of macrophages. <i>Journal of Clinical Investigation</i> , 2020 , 130, 1629-1631	16.3	3
134	PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2020 , 39, 428-435	3.2	7
133	Humoral immune responses: Unsung heroes of the war on cancer. <i>Seminars in Immunology</i> , 2020 , 49, 101419	10.7	3
132	Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells. <i>Cell Metabolism</i> , 2020 , 32, 420-436.e12	24.6	21
131	CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. <i>Cancer Research</i> , 2020 , 80, 5063-5075	10.1	11
130	BTN3A1 governs antitumor responses by coordinating T _H and T _R cells. <i>Science</i> , 2020 , 369, 942-949	33.3	33
129	Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 1474-1485	12.9	24

128	The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. <i>Immunity</i> , 2020 , 52, 668-682.e7	32.3	38
127	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. <i>Cancer Cell</i> , 2019 , 35, 885-900.e10	24.3	213
126	Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies. <i>Frontiers in Physics</i> , 2019 , 7,	3.9	3
125	ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. <i>Nature Communications</i> , 2019 , 10, 1280	17.4	42
124	Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the KrasG12D+; p53fl/fl; myristolated p110fl/fl ROSA-gfp mouse. <i>PLoS ONE</i> , 2019 , 14, e0212930	3.7	7
123	AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2019 , 79, 5034-5047	10.1	20
122	Estimation of immune cell content in tumor using single-cell RNA-seq reference data. <i>BMC Cancer</i> , 2019 , 19, 715	4.8	19
121	Exosomes Produced by Mesenchymal Stem Cells Drive Differentiation of Myeloid Cells into Immunosuppressive M2-Polarized Macrophages in Breast Cancer. <i>Journal of Immunology</i> , 2019 , 203, 3447-3460	5.3	69
120	Breaking barriers for T cells by targeting the EPHA2/TGF- β /COX-2 axis in pancreatic cancer. <i>Journal of Clinical Investigation</i> , 2019 , 129, 3521-3523	15.9	9
119	Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS5596-TPS5596	2.2	2
118	Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery. <i>JCO Clinical Cancer Informatics</i> , 2019 , 3, 1-16	5.2	13
117	IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment. <i>Oncolmmunology</i> , 2019 , 8, e1515058	7.2	9
116	CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. <i>Nature Communications</i> , 2018 , 9, 631	17.4	55
115	Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. <i>Journal of Leukocyte Biology</i> , 2018 , 103, 799-805	6.5	34
114	Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. <i>Cell Reports</i> , 2018 , 22, 3393-3400	10.6	50
113	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018 , 24, 5347-5356	12.9	140
112	PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. <i>Integrative Cancer Science and Therapeutics</i> , 2018 , 5,	0.3	22
111	Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2018 , 9, 2887	8.4	13

110	IRE1 β BP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. <i>Nature</i> , 2018 , 562, 423-428	50.4	139
109	Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer. <i>Cell</i> , 2018 , 175, 679-694.e22	56.2	205
108	Targeted Therapy and Immunosuppression in the Tumor Microenvironment. <i>Trends in Cancer</i> , 2017 , 3, 19-27	12.5	32
107	SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. <i>Immunity</i> , 2017 , 46, 51-64	32.3	83
106	Immunotherapy for Breast Cancer: Current and Future Strategies. <i>Current Surgery Reports</i> , 2017 , 5, 1	0.5	19
105	ARID1A-mutated ovarian cancers depend on HDAC6 activity. <i>Nature Cell Biology</i> , 2017 , 19, 962-973	23.4	124
104	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2017 , 5, 1152-1161	12.5	181
103	Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. <i>Cancer Discovery</i> , 2017 , 7, 72-85	24.4	102
102	Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. <i>Clinical Cancer Research</i> , 2017 , 23, 441-453	12.9	52
101	BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. <i>Cell Reports</i> , 2016 , 16, 2829-2837	10.6	226
100	Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. <i>Oncogenesis</i> , 2016 , 5, e267	6.6	23
99	BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. <i>Cancer Research</i> , 2016 , 76, 6320-6330	10.1	85
98	Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis. <i>Cancer Research</i> , 2016 , 76, 6253-6265	10.1	28
97	Galectin-1 is essential for the induction of MOG35-55 -based intravenous tolerance in experimental autoimmune encephalomyelitis. <i>European Journal of Immunology</i> , 2016 , 46, 1783-96	6.1	19
96	IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. <i>Cancer Research</i> , 2016 , 76, 2561-72	10.1	21
95	Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells. <i>Cell Reports</i> , 2016 , 14, 1774-1786	10.6	73
94	Local Hyperthermia Treatment of Tumors Induces CD8+ T Cell-Mediated Resistance Against Distal and Secondary Tumors. <i>Frontiers in Nanobiomedical Research</i> , 2016 , 309-347		3
93	Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. <i>Cancer Cell</i> , 2016 , 30, 120-135	24.3	200

92	Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. <i>Signal Transduction and Targeted Therapy</i> , 2016 , 1,	21	58
91	Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways. <i>Journal of Molecular Biology</i> , 2016 , 428, 3266-3281	6.5	55
90	State-of-the-art of regulatory dendritic cells in cancer. <i>Pharmacology & Therapeutics</i> , 2016 , 164, 97-104	13.9	27
89	Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. <i>Cancer Research</i> , 2016 , 76, 6964-6974	10.1	200
88	The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level. <i>Molecular and Cellular Proteomics</i> , 2016 , 15, 3348-3360	7.6	15
87	Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model. <i>Vaccine</i> , 2015 , 33, 4313-20	4.1	26
86	TLR5 signaling, commensal microbiota and systemic tumor promoting inflammation: the three parcae of malignant progression. <i>OncImmunology</i> , 2015 , 4, e1021542	7.2	6
85	Telomeric repeat-containing RNA (TERRA) constitutes a nucleoprotein component of extracellular inflammatory exosomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E6293-300	11.5	60
84	Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. <i>Cancer Cell</i> , 2015 , 27, 27-40	24.3	180
83	Myristoylated p110 α Causes Embryonic Death Due to Developmental and Vascular Defects. <i>Open Life Sciences</i> , 2015 , 10, 461-478	1.2	4
82	ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. <i>Cell</i> , 2015 , 161, 1527-38	56.2	427
81	The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds. <i>Advances in Cancer Research</i> , 2015 , 128, 235-62	5.9	38
80	Small but Mighty: Selected Commensal Bacterial Species Determine the Effectiveness of Anti-cancer Immunotherapies. <i>Immunity</i> , 2015 , 43, 1037-9	32.3	2
79	Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. <i>Nature Medicine</i> , 2015 , 21, 231-8	50.5	397
78	Size does not matter: commensal microorganisms forge tumor-promoting inflammation and anti-tumor immunity. <i>Oncoscience</i> , 2015 , 2, 239-46	0.8	8
77	Transforming growth factor β -mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. <i>Immunity</i> , 2014 , 41, 427-439	32.3	75
76	Initiation of metastatic breast carcinoma by targeting of the ductal epithelium with adenovirus-cre: a novel transgenic mouse model of breast cancer. <i>Journal of Visualized Experiments</i> , 2014 ,	1.6	13
75	A role for the chemokine receptor CCR6 in mammalian sperm motility and chemotaxis. <i>Journal of Cellular Physiology</i> , 2014 , 229, 68-78	7	35

74	Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. <i>Journal of Clinical Investigation</i> , 2014 , 124, 5466-80	15.9	330
73	Mesothelin expression is associated with poor outcomes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 675-84	4.4	31
72	Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014 , 10, 1273-1285	6	125
71	Fibroblast activation protein, a potential diagnostic and therapeutic target for cancer-reply. <i>Human Pathology</i> , 2014 , 45, 1553-4	3.7	4
70	Mesothelin expression as a predictive biomarker of breast cancer outcomes.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11119-11119	2.2	
69	Reprogramming immune responses via microRNA modulation 2013 , 1,		3
68	Avirulent <i>Toxoplasma gondii</i> generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. <i>Cancer Research</i> , 2013 , 73, 3842-51	10.1	56
67	Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. <i>Human Pathology</i> , 2013 , 44, 2549-57	3.7	55
66	Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. <i>Cell Cycle</i> , 2013 , 12, 2113-9	4.7	61
65	Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. <i>Integrative Biology (United Kingdom)</i> , 2013 , 5, 159-71	3.7	39
64	Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer. <i>Frontiers in Immunology</i> , 2013 , 4, 435	8.4	16
63	Mast cells impair the development of protective anti-tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 2273-82	7.4	32
62	Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. <i>Journal of Experimental Medicine</i> , 2012 , 209, 495-506	16.6	220
61	Formation of telomeric repeat-containing RNA (TERRA) foci in highly proliferating mouse cerebellar neuronal progenitors and medulloblastoma. <i>Journal of Cell Science</i> , 2012 , 125, 4383-94	5.3	49
60	Anti-tumor immunity: myeloid leukocytes control the immune landscape. <i>Cellular Immunology</i> , 2012 , 278, 21-6	4.4	18
59	Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. <i>Advances in Pharmacology</i> , 2012 , 65, 45-61	5.7	50
58	Mesothelin, a novel immunotherapy target for triple negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 799-804	4.4	94
57	Does the F508-CFTR mutation induce a proinflammatory response in human airway epithelial cells?. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2012 , 303, L509-18	5.8	19

56	Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles. <i>OncImmunology</i> , 2012 , 1, 968-970	7.2	11
55	Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. <i>Cancer Research</i> , 2012 , 72, 1683-93	10.1	118
54	Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy. <i>Expert Review of Obstetrics and Gynecology</i> , 2012 , 7, 413-419		11
53	Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. <i>Clinical Cancer Research</i> , 2010 , 16, 4246-55	12.9	95
52	Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity. <i>Clinical and Developmental Immunology</i> , 2010 , 2010, 139304		4
51	CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. <i>Journal of Immunology</i> , 2010 , 184, 5654-62	5.3	67
50	Mycobacterium tuberculosis infection induces il12rb1 splicing to generate a novel IL-12Rbeta1 isoform that enhances DC migration. <i>Journal of Experimental Medicine</i> , 2010 , 207, 591-605	16.6	34
49	Mycobacterium tuberculosis infection induces il12rb1 splicing to generate a novel IL-12Rβ1 isoform that enhances DC migration. <i>Journal of Experimental Medicine</i> , 2010 , 207, 897-897	16.6	78
48	Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. <i>Cell Cycle</i> , 2010 , 9, 260-8	4.7	35
47	CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. <i>Oncotarget</i> , 2010 , 1, 329-38	3.3	54
46	In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. <i>Cancer Research</i> , 2009 , 69, 7329-37	10.1	106
45	CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. <i>Cancer Research</i> , 2009 , 69, 6331-8	10.1	46
44	Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. <i>Journal of Translational Medicine</i> , 2009 , 7, 49	8.5	47
43	Human uterine NK cells interact with uterine macrophages via NKG2D upon stimulation with PAMPs. <i>American Journal of Reproductive Immunology</i> , 2009 , 61, 52-61	3.8	24
42	Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. <i>Journal of Clinical Investigation</i> , 2009 , 119, 2231-44	15.9	158
41	Inflammatory and immune responses induced by nanomaterials: challenges and opportunities for future nanotherapies. <i>Nanotechnology Perceptions</i> , 2009 , 5, 195-203	1.5	1
40	Estradiol regulates MICA expression in human endometrial cells. <i>Clinical Immunology</i> , 2008 , 129, 325-329		14
39	Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. <i>Cancer Research</i> , 2008 , 68, 7684-91	10.1	92

38	PILAR is a novel modulator of human T-cell expansion. <i>Blood</i> , 2008 , 112, 1259-68	2.2	36
37	Estradiol induces NKG2D ligand expression in human endometrial epithelium. <i>FASEB Journal</i> , 2008 , 22, 853-10	0.9	1
36	Role of vascular leukocytes in ovarian cancer neovascularization. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 622, 273-80	3.6	9
35	Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. <i>Cancer Research</i> , 2007 , 67, 4783-9	10.1	74
34	Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. <i>Cancer Research</i> , 2007 , 67, 5003-8	10.1	79
33	Vascular leukocytes: a population with angiogenic and immunosuppressive properties highly represented in ovarian cancer. <i>Advances in Experimental Medicine and Biology</i> , 2007 , 590, 185-93	3.6	17
32	Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. <i>Cancer Biology and Therapy</i> , 2006 , 5, 635-42	4.6	56
31	Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. <i>Cancer Biology and Therapy</i> , 2006 , 5, 867-74	4.6	18
30	Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines. <i>Cancer Gene Therapy</i> , 2006 , 13, 182-93	5.4	18
29	Immunotherapy for gynaecological malignancies. <i>Expert Opinion on Biological Therapy</i> , 2005 , 5, 1193-210	5.4	30
28	Vascular leukocytes contribute to tumor vascularization. <i>Blood</i> , 2005 , 105, 679-81	2.2	171
27	The role of dendritic cell precursors in tumour vasculogenesis. <i>British Journal of Cancer</i> , 2005 , 92, 1182-78	7	96
26	Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. <i>Human Gene Therapy</i> , 2005 , 16, 765-78	4.8	70
25	HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. <i>Molecular Therapy</i> , 2005 , 12, 789-802	11.7	102
24	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. <i>Nature Medicine</i> , 2004 , 10, 942-9	50.5	3866
23	Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. <i>Nature Medicine</i> , 2004 , 10, 950-8	50.5	385
22	Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. <i>Cancer Research</i> , 2004 , 64, 2175-82	10.1	59
21	Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. <i>Cancer Biology and Therapy</i> , 2003 , 2, 446-51	4.6	50

20	T cells in ovarian cancer. <i>New England Journal of Medicine</i> , 2003 , 348, 1814; author reply 1814	59.2	1
19	Antioxidant nutrients protect against cyclosporine A nephrotoxicity. <i>Toxicology</i> , 2003 , 189, 99-111	4.4	98
18	Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. <i>New England Journal of Medicine</i> , 2003 , 348, 203-13	59.2	2446
17	Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver. <i>Protein Science</i> , 2003 , 12, 143-52	6.3	112
16	Distribution of new human beta-defensin genes clustered on chromosome 20 in functionally different segments of epididymis. <i>Genomics</i> , 2003 , 81, 175-83	4.3	94
15	Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. <i>American Journal of Pathology</i> , 2002 , 161, 2295-309	5.8	111
14	Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2002 , 292, 860-8	3.4	61
13	Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of <i>Xenopus</i> oocytes and the induction of macrophage chemoattraction. <i>Cell and Tissue Research</i> , 2001 , 306, 257-64	4.2	313
12	NK-1 receptor gene expression is related to pain in chronic pancreatitis. <i>Pain</i> , 2001 , 91, 209-217	8	74
11	Real-time quantitative PCR of telomerase mRNA is useful for the differentiation of benign and malignant pancreatic disorders. <i>Pancreas</i> , 2001 , 22, 331-40	2.6	22
10	Structure determination of human and murine beta-defensins reveals structural conservation in the absence of significant sequence similarity. <i>Protein Science</i> , 2001 , 10, 2470-2479	6.3	108
9	Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. <i>International Journal of Cancer</i> , 2000 , 88, 12-20	7.5	115
8	Macrophages infiltrating the tissue in chronic pancreatitis express the chemokine receptor CCR5. <i>Surgery</i> , 2000 , 128, 806-14	3.6	58
7	Interference of chylomicrons in analysis of platelets by flow cytometry. <i>Thrombosis Research</i> , 1998 , 91, 49-52	8.2	12
6	Increased hydrogen peroxide formation in polymorphonuclear leukocytes of IDDM patients. <i>Diabetes Care</i> , 1998 , 21, 326-7	14.6	13
5	Cyclosporine increases local glomerular synthesis of reactive oxygen species in rats: effect of vitamin E on cyclosporine nephrotoxicity. <i>Transplantation</i> , 1998 , 66, 1325-9	1.8	48
4	Interference from lipemia in cell count by hematology analyzers. <i>Clinical Chemistry</i> , 1996 , 42, 987-988	5.5	19
3	Evaluation of zone electrophoresis of serum proteins performed on the Helena Laboratories rapid electrophoresis analyser. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1995 , 55, 729-31	2	2

2	VALIS: Virtual Alignment of pathoLogY Image Series	1
1	DNA methylation-based immune cell deconvolution in solid tumors	1